Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz269.040
Abstract: Abstract Background Immune checkpoint inhibitors mediated by PD-1 and PD-L1 are promising treatments for various tumors. The PD-L1 expression in tumor cells was found to be correlated with the likelihood of a response to PD-1-… read more here.
Keywords: ihc 22c3; short duration; prevalence; 22c3 pharmdx ... See more keywords
Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263
Sign Up to like & getrecommendations! Published in 2018 at "AntiCancer Research"
DOI: 10.21873/anticanres.13065
Abstract: Background/Aim: While the PD-L1 22C3 pharmDx assay is an FDA-approved diagnostic assay for pembrolizumab use, not every pathology laboratory has the Dako Autostainer to use this assay. Since Ventana BenchMark platforms are more common, the… read more here.
Keywords: non small; two assays; cell lung; lung cancer ... See more keywords
PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays
Sign Up to like & getrecommendations! Published in 2022 at "Pathology and Oncology Research"
DOI: 10.3389/pore.2022.1610260
Abstract: Immune checkpoint blockade (ICB) drugs are a novel, effective treatment for advanced urothelial carcinoma. Worldwide, several different ICB drugs are approved, each developed and clinically validated with a specific PD-L1 compound diagnostic assay. As a… read more here.
Keywords: sp142 assays; icb drugs; urothelial carcinoma; 22c3 pharmdx ... See more keywords